A dual, reversible EGFR/ErbB2 inhibitor, lapatinib (Tykerb) in particular has demonstrated significant activity in ErbB2-positive breast cancers and now is approved to be used in this indication [13]. The gene discussed is EGFR; the disease is breast cancer.